Trials / Completed
CompletedNCT03031522
EGFR Molecular Classification In Vivo
Molecular Imaging to Identify EGFR-TKIs Benefit Non-small Cell Lung Carcinoma Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Harbin Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The investigators developed 18F-IRS as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-activating mutational status.
Detailed description
The goal of investigators were to evaluate the use of 18F-IRS as a novel PET/CT radiotracer to monitor EGFR-activating mutational status and identify EGFR-TKIs benefit NSCLC patients. the investigators want to evaluated the use of 18F-IRS in lung cancer imaging in adult NSCLC patients with different EGFR mutational status of primary and metastatic cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | 18F-IRS | According to experiment, 18F-IRS was non-toxic and stable in serum. |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
- First posted
- 2017-01-25
- Last updated
- 2020-02-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03031522. Inclusion in this directory is not an endorsement.